Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Astria Therapeutics Inc ATXS

Healthcare Biotechnology
Astria Therapeutics, Inc. is a biopharmaceutical company focused on developing therapies for allergic and immunological diseases. The Company's lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in clinical development for the treatment of hereditary angioedema (HAE), a rare, debilitating and potentially life-threatening disease. Its second program, STAR-0310, is a... see more

Recent & Breaking News (NDAQ:ATXS)

Astria Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Business Wire September 2, 2022

Astria Therapeutics Reports Second Quarter 2022 Financial Results and Provides a Corporate Update

Business Wire August 9, 2022

Astria Therapeutics Announces Initiation of Phase 1a Trial of STAR-0215, a Monoclonal Antibody Inhibitor of Plasma Kallikrein for Treatment of Hereditary Angioedema

Business Wire August 4, 2022

Astria Therapeutics to Present at Upcoming Wedbush PacGrow Healthcare Conference 2022

Business Wire August 3, 2022

Astria Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Business Wire August 2, 2022

Astria Therapeutics Announces FDA Clearance of IND Application for STAR-0215, a Monoclonal Antibody Inhibitor of Plasma Kallikrein for Treatment of Hereditary Angioedema

Business Wire July 28, 2022

Astria Therapeutics Names Chris Morabito Chief Medical Officer

Business Wire July 15, 2022

Astria Therapeutics to Participate in Virtual Fireside Chat at Upcoming H.C. Wainwright 1st Annual Hereditary Angioedema Conference

Business Wire July 14, 2022

Astria Therapeutics Presents New Preclinical Data Showing Differentiated Profile of STAR-0215, in Development for Treatment of Hereditary Angioedema

Business Wire July 5, 2022

Astria Therapeutics to Present New Preclinical STAR-0215 Data at the European Academy of Allergy and Clinical Immunology 2022 Hybrid Congress

Business Wire June 23, 2022

Astria Therapeutics to Present at Upcoming Jefferies Healthcare Conference

Business Wire June 3, 2022

Astria Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Business Wire June 2, 2022

Astria Therapeutics Reports First Quarter 2022 Financial Results and Provides a Corporate Update

Business Wire May 12, 2022

Astria Therapeutics to Present STAR-0215 Data at the 2022 Fc Receptor and IgG Targeted Therapies Conference

Business Wire April 21, 2022

Astria Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Business Wire April 4, 2022

Astria Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results and Provides a Corporate Update

Business Wire March 10, 2022

Astria Therapeutics to Participate in Upcoming Investor Conferences

Business Wire March 9, 2022

Astria Therapeutics to Present STAR-0215 Data at the 2022 American Academy of Allergy, Asthma and Immunology Annual Meeting

Business Wire February 18, 2022

Astria Therapeutics Reports Third Quarter 2021 Financial Results and Provides a Corporate Update

Business Wire November 10, 2021

Astria Therapeutics to Present at Upcoming Jefferies London Healthcare Conference

Business Wire November 9, 2021